Login
Navigate Fool.com
Will GERN beat
the market?

Geron Corp

NASDAQ: GERN

Community Rating: 2 Stars: Unattractive

2.03 0.03 (1.50%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.07
Previous Close $2.00
Daily Range $1.95 - $2.12
52-Week Range $1.05 - $7.79
Market Cap $318.5M
P/E Ratio -6.67
Dividend (Yield) $0.00 (0.0%)
Volume 3,325,350
Average Daily Volume 8,071,234
Current FY EPS -$0.24

How do you think GERN
will perform against the market?

Top GERN Bull/Bear Pitches

 

BlacknGold (< 20)
Submitted April 25, 2011

Cancer vaccines based on telomerase reverse transcriptase (TERT), which repairs damaged telomeres. Telomeres are the caps at the end of chromosomes. These shorten every time a cell divides as a natura … More

2 Replies Reply Report this Post
 

SwingCorey (< 20)
Submitted January 11, 2010

Embryonic stem cell research, regardless of the current presidential/congressional support, is in trouble. They have not figured out how to fix the problems (e.g. cancerous tumors), yet "adult" stem … More

2 Replies Reply Report this Post

News & Commentary

5 Unlikely Companies Bucking the Biotech Sell-Off

The SPDR S&P Biotech ETF is down 22.4% over the trailing month, but these five biotech stocks are all up. What's their secret?

Tuesday's ETF Movers: XBI, ILF

Shorts Are Piling Into These Stocks. Should You Be Worried?

Do short-sellers have these three stocks pegged? You be the judge!

Nasdaq Falls Below 4,000 on Biotech, Technology Weakness

Is Now the Time to Invest in Agios Pharmaceuticals, Inc?

Agios Pharmaceuticals reported surprisingly strong results for an early stage blood cancer drug candidate today. Should you dig deeper into this story?

Are These 3 Biotechs Bad News Buys?

With biotech stocks taking a step back in March, let's review three of the biggest busts of the sector over the past month

Noteworthy ETF Outflows: XBI, GERN, ACHN, EXAS

The Week's Worst Clinical Failures

See which companies suffered the worst clinical setbacks last week.

After-Hours Earnings Report for March 25, 2014 : PVH, FIVE, SCS, GERN, LNDC, GOL, EXFO, AXU, HTM, G

After-Hours Earnings Report for March 25, 2014 : PVH, FIVE, SCS, GERN, LNDC, GOL, EXFO, AXU, HTM, GEVO, CYCC, WLDN

Tuesday's ETF Movers: GDXJ, XBI

See More GERN News...

Sector

Healthcare

Industry

Drugs

Geron Corp (GERN) Description

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. Website: http://www.geron.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks